Dosage and Adverse Effects of Topical Tacrolimus and Steroids in Daily Management of Atopic Dermatitis

Masutaka Furue, Hiroshi Terao, Yoichi Moroi, Tetsuya Koga, Yumiko Kubota, Juichiro Nakayama, Fukumi Furukawa, Yoichi Tanaka, Ichiro Katayama, Naoko Kinukawa, Yoshiaki Nose, Kazunori Urabe

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Since 1999, combination therapy with tacrolimus and topical steroids has been widely used for the treatment of adolescent/adult-type atopic dermatitis. In order to determine the clinical doses of topical tacrolimus and steroids for daily treatment of atopic dermatitis and to elucidate their beneficial and adverse effects, we analyzed the clinical data from 215 patients with atopic dermatitis who were more than 16 years old. Less than 70g of tacrolimus and less than 15 g of steroids were applied to 90% of the patients on the face and neck, and less than 75.8 g of tacrolimus and less than 322 g of steroids were applied to 90% of the patients on the trunk and extremities during the six-month treatment period. Topical tacrolimus is much more frequently used on face and neck lesions (99.1%); in only 39.5% of cases was it used on the trunk and extremities. The majority of patients improved after six months of the combination topical therapy; however, atopic dermatitis was not controlled in 6% of the patients. The combination therapy did not seem to increase the risk of cutaneous infections; however, the incidence of herpes simplex infection on the face and neck was 2.8% at pre-treatment and slightly increased to 4.7% during the therapy. The incidence of all steroid-induced adverse effects was reduced both in frequency and intensity with a decrease in the dose of topical steroids through simultaneous tacrolimus application. Combination therapy with topical tacrolimus and steroids is useful for treating atopic dermatitis, but a small percentage of the patients still cannot be satisfactorily treated. For such patients, adjustments of the dose and rank of topical steroids and tacrolimus and other therapeutic adjuncts are necessary.

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalJournal of Dermatology
Volume31
Issue number4
DOIs
Publication statusPublished - Jan 1 2004

Fingerprint

Tacrolimus
Atopic Dermatitis
Steroids
Therapeutics
Neck
Extremities
Herpes Simplex
Incidence
Infection
Skin

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Dosage and Adverse Effects of Topical Tacrolimus and Steroids in Daily Management of Atopic Dermatitis. / Furue, Masutaka; Terao, Hiroshi; Moroi, Yoichi; Koga, Tetsuya; Kubota, Yumiko; Nakayama, Juichiro; Furukawa, Fukumi; Tanaka, Yoichi; Katayama, Ichiro; Kinukawa, Naoko; Nose, Yoshiaki; Urabe, Kazunori.

In: Journal of Dermatology, Vol. 31, No. 4, 01.01.2004, p. 277-283.

Research output: Contribution to journalArticle

Furue, M, Terao, H, Moroi, Y, Koga, T, Kubota, Y, Nakayama, J, Furukawa, F, Tanaka, Y, Katayama, I, Kinukawa, N, Nose, Y & Urabe, K 2004, 'Dosage and Adverse Effects of Topical Tacrolimus and Steroids in Daily Management of Atopic Dermatitis', Journal of Dermatology, vol. 31, no. 4, pp. 277-283. https://doi.org/10.1111/j.1346-8138.2004.tb00673.x
Furue, Masutaka ; Terao, Hiroshi ; Moroi, Yoichi ; Koga, Tetsuya ; Kubota, Yumiko ; Nakayama, Juichiro ; Furukawa, Fukumi ; Tanaka, Yoichi ; Katayama, Ichiro ; Kinukawa, Naoko ; Nose, Yoshiaki ; Urabe, Kazunori. / Dosage and Adverse Effects of Topical Tacrolimus and Steroids in Daily Management of Atopic Dermatitis. In: Journal of Dermatology. 2004 ; Vol. 31, No. 4. pp. 277-283.
@article{ce70b870a27e469e9f35003f82a94208,
title = "Dosage and Adverse Effects of Topical Tacrolimus and Steroids in Daily Management of Atopic Dermatitis",
abstract = "Since 1999, combination therapy with tacrolimus and topical steroids has been widely used for the treatment of adolescent/adult-type atopic dermatitis. In order to determine the clinical doses of topical tacrolimus and steroids for daily treatment of atopic dermatitis and to elucidate their beneficial and adverse effects, we analyzed the clinical data from 215 patients with atopic dermatitis who were more than 16 years old. Less than 70g of tacrolimus and less than 15 g of steroids were applied to 90{\%} of the patients on the face and neck, and less than 75.8 g of tacrolimus and less than 322 g of steroids were applied to 90{\%} of the patients on the trunk and extremities during the six-month treatment period. Topical tacrolimus is much more frequently used on face and neck lesions (99.1{\%}); in only 39.5{\%} of cases was it used on the trunk and extremities. The majority of patients improved after six months of the combination topical therapy; however, atopic dermatitis was not controlled in 6{\%} of the patients. The combination therapy did not seem to increase the risk of cutaneous infections; however, the incidence of herpes simplex infection on the face and neck was 2.8{\%} at pre-treatment and slightly increased to 4.7{\%} during the therapy. The incidence of all steroid-induced adverse effects was reduced both in frequency and intensity with a decrease in the dose of topical steroids through simultaneous tacrolimus application. Combination therapy with topical tacrolimus and steroids is useful for treating atopic dermatitis, but a small percentage of the patients still cannot be satisfactorily treated. For such patients, adjustments of the dose and rank of topical steroids and tacrolimus and other therapeutic adjuncts are necessary.",
author = "Masutaka Furue and Hiroshi Terao and Yoichi Moroi and Tetsuya Koga and Yumiko Kubota and Juichiro Nakayama and Fukumi Furukawa and Yoichi Tanaka and Ichiro Katayama and Naoko Kinukawa and Yoshiaki Nose and Kazunori Urabe",
year = "2004",
month = "1",
day = "1",
doi = "10.1111/j.1346-8138.2004.tb00673.x",
language = "English",
volume = "31",
pages = "277--283",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Dosage and Adverse Effects of Topical Tacrolimus and Steroids in Daily Management of Atopic Dermatitis

AU - Furue, Masutaka

AU - Terao, Hiroshi

AU - Moroi, Yoichi

AU - Koga, Tetsuya

AU - Kubota, Yumiko

AU - Nakayama, Juichiro

AU - Furukawa, Fukumi

AU - Tanaka, Yoichi

AU - Katayama, Ichiro

AU - Kinukawa, Naoko

AU - Nose, Yoshiaki

AU - Urabe, Kazunori

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Since 1999, combination therapy with tacrolimus and topical steroids has been widely used for the treatment of adolescent/adult-type atopic dermatitis. In order to determine the clinical doses of topical tacrolimus and steroids for daily treatment of atopic dermatitis and to elucidate their beneficial and adverse effects, we analyzed the clinical data from 215 patients with atopic dermatitis who were more than 16 years old. Less than 70g of tacrolimus and less than 15 g of steroids were applied to 90% of the patients on the face and neck, and less than 75.8 g of tacrolimus and less than 322 g of steroids were applied to 90% of the patients on the trunk and extremities during the six-month treatment period. Topical tacrolimus is much more frequently used on face and neck lesions (99.1%); in only 39.5% of cases was it used on the trunk and extremities. The majority of patients improved after six months of the combination topical therapy; however, atopic dermatitis was not controlled in 6% of the patients. The combination therapy did not seem to increase the risk of cutaneous infections; however, the incidence of herpes simplex infection on the face and neck was 2.8% at pre-treatment and slightly increased to 4.7% during the therapy. The incidence of all steroid-induced adverse effects was reduced both in frequency and intensity with a decrease in the dose of topical steroids through simultaneous tacrolimus application. Combination therapy with topical tacrolimus and steroids is useful for treating atopic dermatitis, but a small percentage of the patients still cannot be satisfactorily treated. For such patients, adjustments of the dose and rank of topical steroids and tacrolimus and other therapeutic adjuncts are necessary.

AB - Since 1999, combination therapy with tacrolimus and topical steroids has been widely used for the treatment of adolescent/adult-type atopic dermatitis. In order to determine the clinical doses of topical tacrolimus and steroids for daily treatment of atopic dermatitis and to elucidate their beneficial and adverse effects, we analyzed the clinical data from 215 patients with atopic dermatitis who were more than 16 years old. Less than 70g of tacrolimus and less than 15 g of steroids were applied to 90% of the patients on the face and neck, and less than 75.8 g of tacrolimus and less than 322 g of steroids were applied to 90% of the patients on the trunk and extremities during the six-month treatment period. Topical tacrolimus is much more frequently used on face and neck lesions (99.1%); in only 39.5% of cases was it used on the trunk and extremities. The majority of patients improved after six months of the combination topical therapy; however, atopic dermatitis was not controlled in 6% of the patients. The combination therapy did not seem to increase the risk of cutaneous infections; however, the incidence of herpes simplex infection on the face and neck was 2.8% at pre-treatment and slightly increased to 4.7% during the therapy. The incidence of all steroid-induced adverse effects was reduced both in frequency and intensity with a decrease in the dose of topical steroids through simultaneous tacrolimus application. Combination therapy with topical tacrolimus and steroids is useful for treating atopic dermatitis, but a small percentage of the patients still cannot be satisfactorily treated. For such patients, adjustments of the dose and rank of topical steroids and tacrolimus and other therapeutic adjuncts are necessary.

UR - http://www.scopus.com/inward/record.url?scp=2342635897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342635897&partnerID=8YFLogxK

U2 - 10.1111/j.1346-8138.2004.tb00673.x

DO - 10.1111/j.1346-8138.2004.tb00673.x

M3 - Article

C2 - 15187322

AN - SCOPUS:2342635897

VL - 31

SP - 277

EP - 283

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 4

ER -